[1] J.D. Molkentin, E.N. Olson, Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors, Proc. Natl. Acad. Sci. U. S. A. 93 (18) (1996) 9366–9373.
[2] T.A. McKinsey, C.L. Zhang, E.N. Olson, MEF2: a calcium-dependent regulator of cell division, differentiation and death, Trends Biochem. Sci. 27 (1) (2002) 40–47.
[3] M.J. Potthoff, E.N. Olson, MEF2: a central regulator of diverse developmental programs, Development 134 (23) (2007) 4131–4140.
[4] J. Herglotz, L. Unrau, F. Hauschildt, M. Fischer, N. Kriebitzsch, M. Alawi, D. Indenbirken, M. Spohn, U. Muller, M. Ziegler, W. Schuh, H.M. Jack, C. Stocking, Essential control of early B-cell development by Mef2 transcription factors, Blood 127 (5) (2016) 572–581.
[5] L. Ma, J. Liu, L. Liu, G. Duan, Q. Wang, Y. Xu, F. Xia, J. Shan, J. Shen, Z. Yang, P. Bie, Y. Cui, X.W. Bian, J. Prieto, M.A. Avila, C. Qian, Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes, Cancer Res. 74 (5) (2014) 1452–1462.
[6] Y.Y. Zhao, L.N. Zhao, P. Wang, Y.S. Miao, Y.H. Liu, Z.H. Wang, J. Ma, Z. Li, Z.Q. Li, Y.X. Xue, Overexpression of miR-18a negatively regulates myocyte enhancer factor 2D to increase the permeability of the blood-tumor barrier via Kruppel-like factor 4- mediated downregulation of zonula occluden-1, claudin-5, and occludin, J. Neurosci. Res. 93 (12) (2015) 1891–1902.
[7] T. Yasuda, S. Tsuzuki, M. Kawazu, F. Hayakawa, S. Kojima, T. Ueno, N. Imoto, S. Kohsaka, A. Kunita, K. Doi, T. Sakura, T. Yujiri, E. Kondo, K. Fujimaki, Y. Ueda, Y. Aoyama, S. Ohtake, J. Takita, E. Sai, M. Taniwaki, M. Kurokawa, S. Morishita, M. Fukayama, H. Kiyoi, Y. Miyazaki, T. Naoe, H. Mano, Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults, Nat. Genet. 48 (5) (2016) 569–574.
[8] Y.F. Liu, B.Y. Wang, W.N. Zhang, J.Y. Huang, B.S. Li, M. Zhang, L. Jiang, J.F. Li, M.J. Wang, Y.J. Dai, Z.G. Zhang, Q. Wang, J. Kong, B. Chen, Y.M. Zhu, X.Q. Weng, Z.X. Shen, J.M. Li, J. Wang, X.J. Yan, Y. Li, Y.M. Liang, L. Liu, X.Q. Chen, W.G. Zhang, J.S. Yan, J.D. Hu, S.H. Shen, J. Chen, L.J. Gu, D. Pei, Y. Li, G. Wu, X. Zhou, R.B. Ren, C. Cheng, J.J. Yang, K.K. Wang, S.Y. Wang, J. Zhang, J.Q. Mi, C.H. Pui, J.Y. Tang, Z. Chen, S.J. Chen, Genomic profiling of adult and pediatric Bcell acute lymphoblastic leukemia, EBioMedicine 8 (2016) 173–183.
[9] Z. Gu, M. Churchman, K. Roberts, Y. Li, Y. Liu, R.C. Harvey, K. McCastlain, S.C. Reshmi, D. Payne-Turner, I. Iacobucci, Y. Shao, I.M. Chen, M. Valentine, D. Pei, K.L. Mungall, A.J. Mungall, Y. Ma, R. Moore, M. Marra, E. Stonerock, J.M. GastierFoster, M. Devidas, Y. Dai, B. Wood, M. Borowitz, E.E. Larsen, K. Maloney, L.A. Mattano Jr., A. Angiolillo, W.L. Salzer, M.J. Burke, F. Gianni, O. Spinelli, J.P. Radich, M.D. Minden, A.V. Moorman, B. Patel, A.K. Fielding, J.M. Rowe, S.M. Luger, R. Bhatia, I. Aldoss, S.J. Forman, J. Kohlschmidt, K. Mrozek, G. Marcucci, C.D. Bloomfield, W. Stock, S. Kornblau, H.M. Kantarjian, M. Konopleva, E. Paietta, C.L. Willman, M.L. Loh, S.P. Hunger, C.G. Mullighan, Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia, Nat. Commun. 7 (2016) 13331.
[10] D. Hirano, F. Hayakawa, T. Yasuda, N. Tange, H. Yamamoto, Y. Kojima, T. Morishita, N. Imoto, S. Tsuzuki, H. Mano, T. Naoe, H. Kiyoi, Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity, Oncogene 38 (13) (2019) 2263–2274.
[11] A. Cesano, R. O’Connor, B. Lange, J. Finan, G. Rovera, D. Santoli, Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice, Blood 77 (11) (1991) 2463–2474.
[12] M. Suzuki, A. Abe, S. Imagama, Y. Nomura, R. Tanizaki, Y. Minami, F. Hayakawa, Y. Ito, A. Katsumi, K. Yamamoto, N. Emi, H. Kiyoi, T. Naoe, BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4, Eur. J. Haematol. 84 (3) (2010) 229–238.
[13] M. Yoshinari, M. Imaizumi, M. Eguchi, M. Ogasawara, T. Saito, H. Suzuki, Y. Koizumi, Y. Cui, A. Sato, T. Saisho, R. Ichinohasama, Y. Matsubara, N. Kamada, K. Iinuma, Establishment of a novel cell line (TS-2) of pre-B acute lymphoblastic leukemia with a t(1;19) not involving the E2A gene, Cancer Genet. Cytogenet. 101 (2) (1998) 95–102.
[14] F. Hayakawa, M.L. Privalsky, Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis, Cancer Cell 5 (4) (2004) 389–401.
[15] V. Prima, L. Gore, A. Caires, T. Boomer, M. Yoshinari, M. Imaizumi, M. VarellaGarcia, S.P. Hunger, Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia, Leukemia 19 (5) (2005) 806–813.
[16] S. Gregoire, A.M. Tremblay, L. Xiao, Q. Yang, K. Ma, J. Nie, Z. Mao, Z. Wu, V. Giguere, X.J. Yang, Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation, J. Biol. Chem. 281 (7) (2006) 4423–4433.
[17] Y. Kato, M. Zhao, A. Morikawa, T. Sugiyama, D. Chakravortty, N. Koide, T. Yoshida, R.I. Tapping, Y. Yang, T. Yokochi, J.D. Lee, Big mitogen-activated kinase regulates multiple members of the MEF2 protein family, J. Biol. Chem. 275 (24) (2000) 18534–18540.
[18] Q. Yang, H. She, M. Gearing, E. Colla, M. Lee, J.J. Shacka, Z. Mao, Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy, Science 323 (5910) (2009) 124–127.
[19] U. Fischer, R.U. Janicke, K. Schulze-Osthoff, Many cuts to ruin: a comprehensive update of caspase substrates, Cell Death Differ. 10 (1) (2003) 76–100.
[20] H.R. Stennicke, M. Renatus, M. Meldal, G.S. Salvesen, Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8, Biochem. J. 350 (Pt 2) (2000) 563–568.
[21] J. Song, H. Tan, H. Shen, K. Mahmood, S.E. Boyd, G.I. Webb, T. Akutsu, J.C. Whisstock, Cascleave: towards more accurate prediction of caspase substrate cleavage sites, Bioinformatics 26 (6) (2010) 752–760.
[22] L.M. Juarez-Salcedo, V. Desai, S. Dalia, Venetoclax: evidence to date and clinical potential, Drugs Context 8 (2019) 212574.
[23] T. Ito, H. Ando, T. Suzuki, T. Ogura, K. Hotta, Y. Imamura, Y. Yamaguchi, H. Handa, Identification of a primary target of thalidomide teratogenicity, Science 327 (5971) (2010) 1345–1350.
[24] J. Kronke, N.D. Udeshi, A. Narla, P. Grauman, S.N. Hurst, M. McConkey, T. Svinkina, D. Heckl, E. Comer, X. Li, C. Ciarlo, E. Hartman, N. Munshi, M. Schenone, S.L. Schreiber, S.A. Carr, B.L. Ebert, Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells, Science 343 (6168) (2014) 301–305.
[25] T. Uehara, Y. Minoshima, K. Sagane, N.H. Sugi, K.O. Mitsuhashi, N. Yamamoto, H. Kamiyama, K. Takahashi, Y. Kotake, M. Uesugi, A. Yokoi, A. Inoue, T. Yoshida, M. Mabuchi, A. Tanaka, T. Owa, Selective degradation of splicing factor CAPERalpha by anticancer sulfonamides, Nat. Chem. Biol. 13 (6) (2017) 675–680.
[26] T. Han, M. Goralski, N. Gaskill, E. Capota, J. Kim, T.C. Ting, Y. Xie, N.S. Williams, D. Nijhawan, Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15, Science 356 (6336) (2017).
[27] J. Manns, M. Daubrawa, S. Driessen, F. Paasch, N. Hoffmann, A. Loffler, K. Lauber, A. Dieterle, S. Alers, T. Iftner, K. Schulze-Osthoff, B. Stork, S. Wesselborg, Triggering of a novel intrinsic apoptosis pathway by the kinase inhibitor staurosporine: activation of caspase-9 in the absence of Apaf-1, FASEB J. 25 (9) (2011) 3250–3261.
[28] C.A. Belmokhtar, J. Hillion, E. Segal-Bendirdjian, Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms, Oncogene 20 (26) (2001) 3354–3362.
[29] S. Tsuzuki, T. Yasuda, S. Kojima, M. Kawazu, K. Akahane, T. Inukai, M. Imaizumi, T. Morishita, K. Miyamura, T. Ueno, S. Karnan, A. Ota, T. Hyodo, H. Konishi, M. Sanada, H. Nagai, K. Horibe, A. Tomita, K. Suzuki, H. Muramatsu, Y. Takahashi, Y. Miyazaki, I. Matsumura, H. Kiyoi, Y. Hosokawa, H. Mano, F. Hayakawa, Targeting MEF2D-fusion oncogenic transcriptional circuitries in B-cell precursor acute lymphoblastic leukemia, Blood Cancer Discovery, in press.
[30] E.A. Sausville, S.G. Arbuck, R. Messmann, D. Headlee, K.S. Bauer, R.M. Lush, A. Murgo, W.D. Figg, T. Lahusen, S. Jaken, X. Jing, M. Roberge, E. Fuse, T. Kuwabara, A.M. Senderowicz, Phase I trial of 72-hour continuous infusion UCN01 in patients with refractory neoplasms, J. Clin. Oncol. 19 (8) (2001) 2319–2333.